Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

Haematologica. 2016 Apr;101(4):e149-52. doi: 10.3324/haematol.2015.132431. Epub 2015 Dec 11.
No abstract available

Keywords: VRD; escalated dose; first relapse; multiple myeloma.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bortezomib / therapeutic use*
  • Dexamethasone / therapeutic use*
  • Drug Administration Schedule
  • Drug Dosage Calculations
  • Female
  • Humans
  • Lenalidomide
  • Logistic Models
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology
  • Neoplasms, Second Primary / complications
  • Neoplasms, Second Primary / drug therapy*
  • Neoplasms, Second Primary / mortality
  • Neoplasms, Second Primary / pathology
  • Recurrence
  • Survival Analysis
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Treatment Outcome

Substances

  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • Lenalidomide